A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer - Poll - MDSpire

A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer

  • By

  • Dan Zhou

  • Beibei Ran

  • Lingkai Kong

  • Yan Liu

  • Lingjun Xiao

  • Xiangmei Chen

  • Wencui Liu

  • Xiao Li

  • Jing Zhang

  • Jiahui Zhang

  • Hao Wu

  • Guang Zhang

  • Xiaosong Gu

  • Wenjie Zhang

  • Junhua Wu

  • Chunping Jiang

  • June 15, 2026

  • 0 min

Share

Original Source(s)

A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer

  • by Dan Zhou, Beibei Ran, Lingkai Kong, Yan Liu, Lingjun Xiao, Xiangmei Chen, Wencui Liu, Xiao Li, Jing Zhang, Jiahui Zhang, Hao Wu, Guang Zhang, Xiaosong Gu, Wenjie Zhang, Junhua Wu, Chunping Jiang

  • June 15, 2026

Related Content

Effectiveness of nurse-led dietary modification recommendations in the management of defecation dysfunction among patients with rectal cancer after sphincter-saving surgery: a scoping review

Editorial: Innovative organoid co-culture systems for enhanced precision medicine in cancer and beyond

CD38+ NK cells: novel players in immunoregulation